secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulgent Genetics, Inc. (FLGT)
CIK:        0001674930
Form:       8-K
Filed at:   2021-11-09T23:59:59+00:00
Accession:  0001564590-21-055725
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulgent Genetics Q3 revenue $227.9M (+124% YoY); raises FY revenue guidance to $930M
--------------------------------------------------------------------------------

- Revenue $227.9M (+124% YoY); core revenue $40.1M (+292% YoY).
- GAAP net income $122.5M ($3.93 diluted EPS); non-GAAP net income $126.3M ($4.05 per share).
- Adjusted EBITDA $167.3M; cash & investments $877.3M as of Sep 30, 2021.
- Full-year 2021 revenue guidance raised to $930M from $800M.
- Billable tests ~2.2M in Q3, more than double Q3 2020.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674930/000156459021055725/0001564590-21-055725-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674930/000156459021055725/flgt-8k_20211109.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-055725

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer